

06 Jan 2021 | Analysis

## QUOTED. 6 January. Christopher Haig.

by

Efemoral Medical believes its FlexStep bioabsorbable stent technology combines the best attributes of balloon-expandable and self-expandable stents to address difficult-to-treat peripheral artery disease. See what Efemoral's CEO, Christopher Haig, said about the technology here.

“We’re not worried about trading off flexibility versus rigidity. We’re just optimizing for rigidity, because the flexibility will come from those inter-scaffold spaces.”– Christopher Haig, CEO, Efemoral

- Find out more: [Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Intra-Scaffold Gaps](#)

[Click here](#) for a free trial of *Medtech Insight*